Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) may safely induce disease remissions in relapsed, refractory myeloma without CRS or ICANS though median PFS was only 6.0 months.”
Authors: Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence Lum, Deborah Glass, Jee Park, Michele Donato, David Siegel, Tania Felizardo and Daniel Fowler.
More posts featuring Robert Orlowski.
